Schistosomiasis Treatment Market Size & Share Analysis - Growth Trends And Forecast (2026 - 2031)

The schistosomiasis treatment market size was valued at USD 73 million in 2025 and estimated to grow from USD 75.64 million in 2026 to reach USD 90.26 million by 2031, at a CAGR of 3.62% during the forecast period (2026-2031). This steady climb is tied to World Health Organization (WHO) elimination targets, broader access to child-friendly medicines and sustained donation programs that keep product volumes high despite narrow commercial margins. Intensified community-wide mass-drug-administration (MDA) campaigns are increasing annual consumption volumes, while arpraziquantel’s pediatric orodispersible tablet (ODT) is opening an untapped preschool segment that once lacked age-appropriate therapy. Alongside this demand uplift, supply shocks from active pharmaceutical ingredient (API) shortages are prompting multisource procurement strategies, and digital platforms are improving stock visibility at sub-national level. Competitive differentiation is shifting away from sheer tablet counts toward formulation innovation, local manufacturing footprints and end-to-end pharmacovigilance capabilities.

WHO’s 2025-30 roadmap calls for treating every person aged 2 years and above when community prevalence exceeds 10%. This change broadens the eligible cohort beyond schoolchildren and addresses adults who sustain transmission reservoirs^{[1]Pediatric Praziquantel Consortium, “New WHO Guidelines for Schistosomiasis,” pediatricpraziquantelconsortium.org}. Tanzania’s three-round campaign cut prevalence from 30.4% to 9.5% in under three years, underscoring the efficacy of high-coverage regimens. Wider coverage immediately boosts praziquantel demand and stresses supply logistics. National programs must now track migrant workers, fishermen and other mobile groups, requiring flexible delivery windows and mobile health teams. Implementation success hinges on reliable tablet forecasting, robust community engagement and adherence monitoring technologies.

The EMA’s 2024 positive scientific opinion and WHO prequalification of arpraziquantel allows procurement for children aged 3 months to 6 years, closing a long-standing therapeutic gap for about 24 million preschoolers in Africa^{[2]European Medicines Agency, “Arpraziquantel Opinion,” ema.europa.eu}. Clinical trials posted cure rates of 88% for S. mansoni and 86% for S. haematobium, matching adult therapy outcomes while improving palatability. The not-for-profit consortium behind the product has negotiated technology transfer to Brazil’s Farmanguinhos, ensuring regional supply security and cost-plus pricing. Pilot ADOPT deployments in Côte d’Ivoire, Kenya and Uganda are demonstrating integration with routine immunization visits, a model likely to accelerate elimination timelines once scaled.

Merck now supplies 250 million tablets annually for free, and national programs such as Ethiopia’s 2030 elimination plan have formally added adults to treatment schedules. Adult inclusion raises per-round volume needs by up to 40% in some districts and demands workplace distribution to reach farmers and fishermen. Storytelling campaigns that highlight occupational risks help drive uptake, while Johnson & Johnson’s extension of the VERMOX donation for soil-transmitted helminths supports integrated community deworming. Sustainability depends on proving transmission interruption and maintaining donor enthusiasm despite plateauing prevalence.

Chitosan-based nanoparticles loaded with praziquantel plus plant-derived compounds have shown >90% cure rates in cultured parasites, suggesting lower dosing and possibly less resistance selection pressure. Early-phase studies also report improved bioavailability and reduced dosing frequency, addressing compliance barriers in adults. While clinical translation remains several years away, national control programs are watching closely as combination regimens could offer fallback options should resistance expand.

Meta-analysis covering East Africa reported cure-rate variability from 97.9% in Rwanda down to 68.4% in Uganda, flagging possible tolerance clusters. Laboratory studies have induced resistant parasite strains, and molecular surveillance is rolling out to detect field mutations. Resistance, if unchecked, could derail elimination objectives because praziquantel is the single widely available anti-schistosomal agent. Control programs are adopting sentinel efficacy monitoring and exploring rotational therapy models with oxamniquine, though cost and supply hurdles remain.

The National Institute for Communicable Diseases signaled shortages through April 2025 after a key supplier halted output for upgrades^{[3]National Institute for Communicable Diseases, “Praziquantel Supply Update,” nicd.ac.za}. Fewer than five manufacturers account for most global API production, concentrating risk. China’s national drug shortage report identified essential parasitic medicines among the 0.41% of compounds in deficit, amplifying pressure on importers. Donor initiatives now require dual-sourcing strategies, and Western governments are co-funding advanced flow-chemistry plants to reshore critical API.